Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of ... were "consistent with the safety profile of the incretin drug class," and will now progress to ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...

Incretin therapies based on GLP-1 receptor agonism aid in the loss of weight in obesity, but a relevant part of this loss (25%-40%) is attributed to loss of lean muscle mass, which raises the risk of ...

Glucagon-like peptide-1 (GLP-1) receptor agonists as incretin mimetics and dipeptidyl peptidase-4 (DPP-4) inhibitors as incretin enhancers are the two classes of incretin-based treatments ...

Roughly three-quarters of people who took both an injectable and pill version of a new GLP-1 weight loss drug in trials ...

"The safety and tolerability profile was consistent with other incretin-based therapies at ... referencing the gut hormones mimicked in early GLP-1 drugs like Byetta and Victoza.

and last month we launched single-dose vials” for self-pay patients “priced at a 50% or greater discount compared to the list price of all other incretin (GLP-1) medicines for obesity.” ...

A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...

Kourtney Kardashian showcased her new signature product, which she describes as a "breakthrough innovation" in weight loss ...

We need to take stock of the promises and limitations of new “miracle” weight loss drugs and treat the cause of weight gain, ...